The link between executive remuneration incentives and regulatory noncompliance
Maandblad voor Accountancy en Bedrijfseconomie · 12.03.2026 · 100 (2) · 59-68
DOI: 10.5117/mab.100.180283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Maandblad voor Accountancy en Bedrijfseconomie, online erschienen am 12.03.2026. Verfasst von Siemen Jan Ruben Bouwmeester und 1 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study examines how executive remuneration structures relate to corporate misconduct in the form of regulatory noncompliance. Using a panel of US firms over the past 25 years, we link subsidiary-level violations of all major areas of corporate regulation (e.g., antitrust or employment law) to parent-company executive remuneration. We find that equity-based compensation is positively associated with regulatory noncompliance, whereas higher fixed remuneration relative to firm size significantly reduces it. These findings provide novel evidence on the unintended consequences of equity-based incentives and are relevant for boards, remuneration committees, and regulators concerned with executive pay design and compliance risks.
Zitieren
APA
Bouwmeester, S. J. R., & Matthaei, E. K. (2026). The link between executive remuneration incentives and regulatory noncompliance. Maandblad voor Accountancy en Bedrijfseconomie, 100(2), 59-68. https://doi.org/10.5117/mab.100.180283
Vancouver
Bouwmeester SJR, Matthaei EK. The link between executive remuneration incentives and regulatory noncompliance. Maandblad voor Accountancy en Bedrijfseconomie. 2026;100(2):59-68. doi:10.5117/mab.100.180283
BibTeX
@article{Bouwmeester2026,
author = {Bouwmeester, Siemen Jan Ruben and Matthaei, Eva Kristina},
title = {The link between executive remuneration incentives and regulatory noncompliance},
journal = {Maandblad voor Accountancy en Bedrijfseconomie},
year = {2026},
volume = {100},
number = {2},
pages = {59--68},
doi = {10.5117/mab.100.180283}
}
EUVIMED